CHEMOTHERAPY CERT STUDY GUIDE 2025/2026 ANSWERS
AND QUESTIONS GRADED A+
✔✔Common non-anthracycline antitumor abx: - ✔✔Actinomycin D
Mitomycin C
Bleomycin
✔✔Monitoring necessary with doxorubicin: - ✔✔Vesicant --> extravasation
Cardiac function
Lifetime dose tracking (cardiotoxicity)
✔✔Lifetime dose of doxorubicin should not exceed: - ✔✔550 mg/m^2
✔✔What cardiac protectant medication can be administered prior to doxorubicin? -
✔✔Dexrazoxane
✔✔Significant side effects of doxorubicin are: - ✔✔Cardiotoxicity
N/V
Mucositis
Diarrhea
Severe myelosuppression
Hepatic impairment
Secondary cancers
✔✔Monitoring necessary with bleomycin: - ✔✔Pulmonary toxicity
Hypersensitivity reactions (esp. in lymphoma patients)
Cutaneous reactions
Lifetime dose tracking (pulmonary toxicity)
✔✔Pulmonary fibrosis is possible when the lifetime dose of bleomycin exceeds: -
✔✔400 units
✔✔What 6 patient characteristics make CINV more likely? - ✔✔1. Younger than 50
years
2. Hx of low alcohol intake
3. Female gender
4. Hx of morning sickness during pregnancy
5. Prone to motion sickness
6. Previous chemotherapy
✔✔Types of CINV: - ✔✔Acute
Delayed
Breakthrough
Anticipatory
Refractory
, ✔✔Define acute CINV - ✔✔Occurring within 24 hours of chemotherapy
✔✔Define delayed CINV - ✔✔Occurring from 24 hours to 5 days after treatment
✔✔Define breakthrough CINV - ✔✔Occurring despite treatment
✔✔Define anticipatory CINV - ✔✔Triggered by taste, odor, memories, visions, or
anxiety related to chemotherapy
✔✔Define refractory CINV - ✔✔Occurring during subsequent cycles when treatment
failed in earlier cycles
✔✔Highly emetogenic chemo (HEC) causes CINV in more than ___% of patients -
✔✔90
✔✔Moderately emetogenic chemo (MEC) causes CINV in patients ___% to ___% of the
time - ✔✔30-90
✔✔Patients on low-potential emetogenic chemo develop CINV ___% to ___% of the
time - ✔✔10-30
✔✔Minimal-risk emetogenic chemo causes CINV less than ___% of the time - ✔✔10
✔✔Common IV HEC drugs include: - ✔✔Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Mechlorethamine
Streptozosin
✔✔Common IV MEC drugs include: - ✔✔Carboplatin
Cytarabine
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Oxaliplatin
✔✔Common low-potential IV emetogenic chemo drugs include: - ✔✔5-FU
Cytarabine
Docetaxel
AND QUESTIONS GRADED A+
✔✔Common non-anthracycline antitumor abx: - ✔✔Actinomycin D
Mitomycin C
Bleomycin
✔✔Monitoring necessary with doxorubicin: - ✔✔Vesicant --> extravasation
Cardiac function
Lifetime dose tracking (cardiotoxicity)
✔✔Lifetime dose of doxorubicin should not exceed: - ✔✔550 mg/m^2
✔✔What cardiac protectant medication can be administered prior to doxorubicin? -
✔✔Dexrazoxane
✔✔Significant side effects of doxorubicin are: - ✔✔Cardiotoxicity
N/V
Mucositis
Diarrhea
Severe myelosuppression
Hepatic impairment
Secondary cancers
✔✔Monitoring necessary with bleomycin: - ✔✔Pulmonary toxicity
Hypersensitivity reactions (esp. in lymphoma patients)
Cutaneous reactions
Lifetime dose tracking (pulmonary toxicity)
✔✔Pulmonary fibrosis is possible when the lifetime dose of bleomycin exceeds: -
✔✔400 units
✔✔What 6 patient characteristics make CINV more likely? - ✔✔1. Younger than 50
years
2. Hx of low alcohol intake
3. Female gender
4. Hx of morning sickness during pregnancy
5. Prone to motion sickness
6. Previous chemotherapy
✔✔Types of CINV: - ✔✔Acute
Delayed
Breakthrough
Anticipatory
Refractory
, ✔✔Define acute CINV - ✔✔Occurring within 24 hours of chemotherapy
✔✔Define delayed CINV - ✔✔Occurring from 24 hours to 5 days after treatment
✔✔Define breakthrough CINV - ✔✔Occurring despite treatment
✔✔Define anticipatory CINV - ✔✔Triggered by taste, odor, memories, visions, or
anxiety related to chemotherapy
✔✔Define refractory CINV - ✔✔Occurring during subsequent cycles when treatment
failed in earlier cycles
✔✔Highly emetogenic chemo (HEC) causes CINV in more than ___% of patients -
✔✔90
✔✔Moderately emetogenic chemo (MEC) causes CINV in patients ___% to ___% of the
time - ✔✔30-90
✔✔Patients on low-potential emetogenic chemo develop CINV ___% to ___% of the
time - ✔✔10-30
✔✔Minimal-risk emetogenic chemo causes CINV less than ___% of the time - ✔✔10
✔✔Common IV HEC drugs include: - ✔✔Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Mechlorethamine
Streptozosin
✔✔Common IV MEC drugs include: - ✔✔Carboplatin
Cytarabine
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Oxaliplatin
✔✔Common low-potential IV emetogenic chemo drugs include: - ✔✔5-FU
Cytarabine
Docetaxel
